Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$265.62
+1.4%		$248.48
$190.75
▼
$267.47
$468.13B0.35.38 million shs5.14 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$270.69
+1.2%		$255.08
$173.33
▼
$276.47
$651.25B0.247.00 million shs6.18 million shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+6.59%+3.43%+22.96%+27.26%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+3.94%+4.38%+15.35%+51.57%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$265.62
+1.4%		$248.48
$190.75
▼
$267.47
$468.13B0.35.38 million shs5.14 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$270.69
+1.2%		$255.08
$173.33
▼
$276.47
$651.25B0.247.00 million shs6.18 million shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%+6.59%+3.43%+22.96%+27.26%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+3.94%+4.38%+15.35%+51.57%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.88
Moderate Buy$275.953.89% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.80
Moderate Buy$268.22-0.91% Downside

Current Analyst Ratings Breakdown

Latest ABBV and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$298.00 ➝ $303.00
8/17/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$295.00 ➝ $300.00
8/13/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$300.00
8/11/2026
AbbVie Inc. stock logo
ABBV
AbbVie
BNP Paribas Exane logo
BNP Paribas Exane
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$218.00 ➝ $247.00
8/6/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$270.00 ➝ $287.00
8/5/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Erste Group Bank AG logo
Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy
8/4/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Buy (B-)
8/4/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$261.00 ➝ $288.00
8/3/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$280.00
8/3/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$296.00
8/3/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$282.00 ➝ $290.00
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$64.39B7.29$15.19 per share17.49($3.33) per share-79.77
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B6.93$14.14 per share19.14$35.26 per share7.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5475.0316.440.889.80%-422.07%14.34%10/30/2026 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6331.3721.152.5821.48%32.42%13.35%10/13/2026 (Estimated)

Latest ABBV and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.61$3.65+$0.04$2.03$16.80 billion$16.99 billion
7/15/2026Q2 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.84$2.90+$0.06$2.27$25.06 billion$25.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.61%+6.80%195.48%53 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.361.98%+5.25%62.11%64 Years

Latest ABBV and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/15/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.17%8/25/20268/25/20269/8/2026
6/18/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.83%7/15/20267/15/20268/14/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.09
0.81

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.41 billionOptionable

Recent News About These Companies

Johnson & Johnson (JNJ) Wins EU Approval For TECVAYLI Combo In Multiple Myeloma
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-wins-eu-130805970.html
The Portfolio Blueprint for Building $19,000 a Month in Dividend Income
 |  247wallst.comhttps://247wallst.com/personal-finance/2026/08/23/the-portfolio-blueprint-for-building-19000-a-month-in-dividend-income/
Johnson & Johnson $JNJ is Pinnacle Associates Ltd.'s Largest Position
August 23 at 4:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-johnson-johnson-jnj-is-pinnacle-associates-ltds-largest-position-2026-08-23/
Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.
August 23 at 4:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-johnson-johnson-jnj-position-reduced-by-oppenheimer-asset-management-inc-2026-08-23/
Johnson & Johnson $JNJ Stock Position Boosted by Osprey Private Wealth LLC
August 23 at 4:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-johnson-johnson-jnj-stock-position-boosted-by-osprey-private-wealth-llc-2026-08-23/
Smith Group Asset Management LLC Purchases 9,575 Shares of Johnson & Johnson $JNJ
August 23 at 4:47 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-smith-group-asset-management-llc-purchases-9575-shares-of-johnson-johnson-jnj-2026-08-23/
Cornerstone Capital Inc. Has $29.22 Million Stake in Johnson & Johnson $JNJ
August 23 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-cornerstone-capital-inc-has-2922-million-stake-in-johnson-johnson-jnj-2026-08-23/
BIP Wealth LLC Has $3.98 Million Position in Johnson & Johnson $JNJ
August 23 at 3:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bip-wealth-llc-has-398-million-position-in-johnson-johnson-jnj-2026-08-23/
Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push
August 22 at 10:31 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4939377-johnson-and-johnson-buy-imaavy-label-expansion-first-and-continued-caplyta-sales-push?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Johnson & Johnson Stock Shines on Dividends and Lung Cancer Bet
August 22 at 11:30 AM  |  tipranks.comhttps://www.tipranks.com/news/weekend-updates/johnson-johnson-stock-shines-on-dividends-and-lung-cancer-bet?utm_source=marketbeat.com&utm_medium=referral
Johnson & Johnson, AbbVie, Chevron, Energy Transfer, Home Depot Shaken
August 22 at 9:11 AM  |  tipranks.comhttps://www.tipranks.com/news/weekend-updates/johnson-johnson-abbvie-chevron-energy-transfer-home-depot-shaken?utm_source=marketbeat.com&utm_medium=referral
4,247 Shares in Johnson & Johnson $JNJ Bought by Xcel Wealth Management LLC
August 22 at 6:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-4247-shares-in-johnson-johnson-jnj-bought-by-xcel-wealth-management-llc-2026-08-22/
Massachusetts Financial Services Co. MA Decreases Stock Position in Johnson & Johnson $JNJ
August 22 at 4:48 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-massachusetts-financial-services-co-ma-decreases-stock-position-in-johnson-johnson-jnj-2026-08-22/
Johnson & Johnson (NYSE:JNJ) Shares Up 1.2% - Here's Why
August 21 at 5:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/johnson-johnson-nysejnj-shares-up-12-heres-why-2026-08-21/
Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update
August 21 at 5:39 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/johnson-johnson-wins-fda-510-154300757.html
HALO Stock Rises 36% in a Month: Here's What You Should Know
August 21 at 5:39 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/halo-stock-rises-36-month-162300468.html
Sector Update: Healthcare Stocks Advance in Afternoon Trading
August 21 at 5:39 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sector-healthcare-stocks-advance-afternoon-174323348.html
Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update
August 21 at 12:46 PM  |  zacks.comhttps://www.zacks.com/stock/news/2978578/johnson-johnson-wins-fda-510-k-clearance-for-monarch-quest-3-update?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2978578
Merck vs. J&J: Which Healthcare Giant Should Investors Choose?
August 21 at 12:38 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-vs-j-j-healthcare-122700673.html
Merck vs. J&J: Which Healthcare Giant Should Investors Choose?
August 21 at 9:31 AM  |  zacks.comhttps://www.zacks.com/stock/news/2978103/merck-vs-j-j-which-healthcare-giant-should-investors-choose?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-2978103
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care
August 21 at 7:37 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/european-commission-approves-johnson-johnson-094000744.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
AbbVie logo on a curved wall in an office lobby, with a laboratory and vials visible nearby.
AbbVie Quietly Solved Its Biggest Problem—Now What?
By Thomas Hughes | August 2, 2026
A candlestick stock price chart overlaid on a blurred urban skyline at dusk.
MarketBeat Week in Review – 08/03 - 08/07
By Chris Markoch | August 8, 2026
AbbVie stock logo

AbbVie NYSE:ABBV

$265.62 +3.79 (+1.45%)
As of 08/21/2026 03:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$270.69 +3.32 (+1.24%)
As of 08/21/2026 03:58 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas